Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
Obesity-induced chronic inflammation is a key component in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and insulin resistance. Increased secretion of pro-inflammatory cytokines by macrophages in metabolic tissues promotes disease progression. In the diet induced obesity mouse (DIO) model, activation of liver resident macrophages, or Kupffer cells (KC), drives inflammatory responses, which recruits circulating macrophages and promotes fatty liver development, and ultimately contributes to impaired hepatic insulin sensitivity. Hepatic macrophage express the highest level of Vitamin D receptor (VDR) among non-parenchymal cells, while VDR expression is very low in hepatocytes. VDR activation exerts anti-inflammatory effects in immune cells. Here we found that VDR activation exhibits strong anti-inflammatory effects in mouse hepatic macrophages, including those isolated from DIO livers, while mice with genetic loss of Vdr developed spontaneous hepatic inflammation at 6 months of age. Under the chronic inflammation conditions of the DIO model, VDR activation by the vitamin D analog calcipotriol reduced liver inflammation and hepatic steatosis, significantly improving insulin sensitivity. The hyperinsulinemic euglycemic clamp revealed that VDR activation greatly increased the glucose infusion rate, while hepatic glucose production was remarkably decreased. Glucose uptake in muscle and adipose did not show similar effects, suggesting that improved hepatic insulin sensitivity is the primary contributor to the beneficial effects of VDR activation. Finally, specifically ablating liver macrophages by treatment with clodronate liposomes largely abolished the beneficial metabolic effects of calcipotriol, confirming that VDR activation in liver macrophages is required for the anti-diabetic effect. Conclusion: Activation of liver macrophage VDR by vitamin D ligands ameliorates liver inflammation, steatosis and insulin resistance. Our results suggest novel therapeutic paradigms for treatment of NAFLD and T2D.